SOUTH SAN FRANCISCO, Calif., June 27, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has been named to the Bay Area News Group's 2016 "Top Workplaces" list. This is the third year in a row that Veracyte has received this prestigious award, which is based solely on an annual survey of Bay Area-company employees.
"I am so honored that our employees are motivated to share their positive perspectives on Veracyte," said Bonnie Anderson, president and chief executive officer of the company. "Their recognition reinforces our determination to ensure they continue to feel valued and fulfilled as our company grows and achieves its ultimate goal of improving the lives of patients."
The Top Workplaces list is determined by results of an employee feedback survey administered by WorkplaceDynamics, LLC, a research firm that specializes in organizational health and workplace improvement. The survey measures several aspects of workplace culture, including alignment, execution, and connection, and organizations must meet strict standards for organizational health to be selected as a "Top Workplace."
The Bay Area News Group published the complete list of Top Workplaces 2016 on Sunday, June 26. The list is available on the Bay Area News Group website.
Veracyte's corporate and industry leadership have been recognized consistently over the past several years. This year, the company received a prestigious Edison Award for the Percepta® Bronchial Genomic Classifier, which is used to improve lung cancer diagnosis. The Edison Awards honor excellence in new product and service development, marketing, human-centered design and innovation. Prior to this, Fast Company named Ms. Anderson to its list of "100 Most Creative People in Business 2015" and the San Francisco Business Times has selected her as one of the "Bay Area's Most Admired CEOs."
Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's Afirma® Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier (GEC) and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for 180 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta® Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer. In the fourth quarter of 2016, Veracyte plans to launch its second pulmonology product, the Envisia™ classifier, to improve diagnosis of interstitial lung diseases including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veracyte-named-a-san-francisco-bay-area-2016-top-workplace-300290329.html